A study of gene-edited T cells to eradicate persistent HIV infection in patients receiving anti-retroviral therapy

Trial Profile

A study of gene-edited T cells to eradicate persistent HIV infection in patients receiving anti-retroviral therapy

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs SB 728 T (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Feb 2018 New trial record
    • 07 Feb 2018 According to a Sangamo Therapeutics media release, the grant from the National Institutes of Health will fund this trial. The principal investigator of the study will be Rafick-Pierre Sekaly. The company anticipates initiating this trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top